Cardior Pharmaceuticals
Cardior Pharmaceuticals is a pioneering biopharmaceutical company focused on discovering and developing RNA-based therapeutics to address the root causes of heart disease. Their mission is to bring transformative treatments and diagnostics to patients worldwide, leveraging deep expertise in non-coding RNA biology to create innovative solutions for cardiac dysfunctions.
Industries
Nr. of Employees
small (1-50)
Cardior Pharmaceuticals
Patents
Products
Clinical candidate: miRNA-132 inhibitor (oligonucleotide)
A chemically optimized antisense oligonucleotide designed to inhibit miR-132 to halt and reverse adverse cardiac remodeling; developed for parenteral/subcutaneous administration and evaluated in Phase 1b and Phase 2 trials.
Preclinical ncRNA modulators for cardiomyopathies
Early-stage and discovery-stage oligonucleotide or ncRNA-modulating programs targeting indications such as hypertrophic and dilated cardiomyopathies.
CE-marked PCR kit for circulating microRNA measurement
A diagnostic PCR kit intended to measure circulating microRNA levels used in clinical studies for pharmacodynamic or biomarker assessments; subject to regulatory certification (CE marking).
Clinical candidate: miRNA-132 inhibitor (oligonucleotide)
A chemically optimized antisense oligonucleotide designed to inhibit miR-132 to halt and reverse adverse cardiac remodeling; developed for parenteral/subcutaneous administration and evaluated in Phase 1b and Phase 2 trials.
Preclinical ncRNA modulators for cardiomyopathies
Early-stage and discovery-stage oligonucleotide or ncRNA-modulating programs targeting indications such as hypertrophic and dilated cardiomyopathies.
CE-marked PCR kit for circulating microRNA measurement
A diagnostic PCR kit intended to measure circulating microRNA levels used in clinical studies for pharmacodynamic or biomarker assessments; subject to regulatory certification (CE marking).
Services
Sponsorship and operational management of multicenter Phase 1 and Phase 2 clinical trials for cardiac therapeutics.
Implementation of GCP/GLP-aligned quality systems, audit programs, and support for regulatory inspections and submissions.
Sponsorship and operational management of multicenter Phase 1 and Phase 2 clinical trials for cardiac therapeutics.
Implementation of GCP/GLP-aligned quality systems, audit programs, and support for regulatory inspections and submissions.
Expertise Areas
- RNA therapeutics development
- Oligonucleotide design and optimization
- Preclinical translational research
- Clinical trial management (Phase 1–2)
Key Technologies
- Antisense oligonucleotides (miRNA inhibitors)
- Non-coding RNA modulation
- PCR-based circulating biomarker assays
- Large-animal cardiovascular models
News & Updates
Event from December 9 to September 11, 2024, in Washington DC, USA.
Event from November 19 to 21, 2024, in London, UK.
Event on November 13, 2024, in Hamburg, Germany.
Announcement of Novo Nordisk's agreement to acquire Cardior for up to 1.025 billion Euros.
Announcement of Dr. Orly Vardeny joining the Board of Directors as a permanent guest.
Announcement of appointment of Axel-Sven Malkomes as CFO.
Event from December 9 to September 11, 2024, in Washington DC, USA.
Event from November 19 to 21, 2024, in London, UK.
Event on November 13, 2024, in Hamburg, Germany.
Announcement of Novo Nordisk's agreement to acquire Cardior for up to 1.025 billion Euros.
Announcement of Dr. Orly Vardeny joining the Board of Directors as a permanent guest.
Announcement of appointment of Axel-Sven Malkomes as CFO.